Nurami Medical Overview
Nurami harnesses nanofibers and novel biomaterials to modernize soft tissue surgical repair. Nurami’s proprietary, electrospun-based platform technology enables the creation of an innovative category of bio surgical implants to seal and heal wounds effectively. These advanced products address complications associated with current soft tissue implants, such as dangerous leaks, and promote healthy tissue formation such as Dura repair as well as other tissue recovery processes. Nurami's first soft-tissue repair product, ArtiFascia, is a multilayer, Dural repair graft made of biocompatible and bioabsorbable polymers with integrated barrier layer and a biomimetic structure of electrospun fibers designed to promote neodura regeneration. ArtiFascia is available for commercial use in the USA and has FDA 510(k) clearance.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
The woman behind the billion-dollar brain surgery breakthrough | CTech
Nurami Medical, co-founded by Nora Nseir and Dr. Amir Bahar, is pioneering a new approach to meningeal tissue repair with innovative products that could transform neurosurgical practices. The company recently completed a $30 million funding round, which will enable it to expand its workforce, build a commercial manufacturing facility, and set up high-grade clean rooms. Nuramis first product has received regulatory approval, and the second product is in the animal testing phase, with human trials next. The market potential for their products is vast, with the primary market valued at $1 billion and additional applications potentially worth tens of billions. The company is evolving from a development-focused entity to one that also manufactures and markets its products.
InvestmentExpandFDA approved/pending approval
growth-positive
Nurami Medical's ArtiFascia® Dura Substitute Receives FDA Clearance
Medical device startup Nurami Medical has received FDA clearance for its nanofiber-based product, ArtiFascia Dura Substitute. The product is a resorbable Dural repair graft used in neurosurgeries. The clearance follows a successful clinical trial involving 85 patients. The product is designed to promote dural tissue regeneration and rapid healing, and to prevent cerebrospinal fluid leakage and bacterial penetration. Sales in the US are set to begin soon.
Customers
Growth-Positive
היישר מגונסון & גונסון: פיטר סטבינס מונה ליו"ר נוראמי מדיקל - וואלה! כסף
Norami Medical, a portfolio company of Almeda Ventures, has appointed Peter Stebbins as the active chairman of the companys board of directors. Stebbins, who recently ended a 30-year career at Johnson & Johnson, joins Norami as the company prepares to receive marketing approval for a product used in brain surgery. The company has recently completed a trial involving 90 patients and is preparing for commercial activity in the US and Europe. Norami Medical, based in Haifa, develops innovative tissue grafts for use in brain surgery and other internal surgeries.
Management ChangesExpand
growth-positive
Nurami seeks FDA, EU approval for soft tissue repair solution
Israeli company Nurami Medical has recruited all the patients for a clinical trial on its product to repair soft tissue damaged during neurosurgery. The clinical trial is being conducted to receive FDA marketing approval in the US and the CE mark in the EU for its first product ARTIFASCIA. Nuramis first product is a patent-protected synthetic implant for restoring and repairing membranes after surgical procedures. The potential market for Nuramis first product is estimated to be worth $1 billion annually and expected to grow to $1.4 billion in 2024. Almeda Ventures has invested $2 million in Nurami as part of its most recent financing round.
Investment
growth-positive
אלמדה ונצ'רס מודיעה על השלמת אבן דרך בחברת פורטפוליו בלומר
Nurami Medical, an Israeli medical technology company, has completed the recruitment of 80% of patients for its clinical trial, bringing it significantly closer to completing its FDA trial. The trial is being conducted to gain regulatory approval for the marketing of Nuramis first product, a biodegradable graft for brain dura repair after surgery. The investment is part of Nuramis last funding round of $5.5 million, led by Almeda Ventures. Nurami has so far raised a total of $5 million from the Innovation Authority and other investors, including NGT3VC and investors from China.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $43.65M |
| Last funding | $30M |
| Stage | B |
| Rounds | 9 |
| Investors | 11 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.nurami-medical.com |
| Careers | Careers page |
Locations
Ha-Namal Street 36, Haifa, Israel
Photos & Videos
2 item(s)
